Exelixis vs Incyte
Exelixis (EXEL) and Incyte (INCY) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $15.8B
- Last close
- $64.63
- 12 months
- +54.7%
- Market value
- $23.4B
- Last close
- $114.63
- 12 months
- +12.6%
At a glance
- The biggest part of Exelixis's revenue is CABOMETYX (91%); at Incyte it is JAKAFI (60%).
- By market value, Incyte ($23.4B) is about 1.5 times Exelixis ($15.8B).
- Over the last 12 months Exelixis's share price moved +54.7% and Incyte's +12.6%; against the S&P 500 that is +49.0 points and +6.9 points.
- In their last fiscal years Exelixis kept 33.7% of revenue as net income and Incyte 25.0%.
- In the last 90 days insiders reported 0 open-market purchases at Exelixis and 0 at Incyte; members of Congress disclosed 0 trades in Exelixis and 0 in Incyte.
- Next results: Exelixis Feb 8, 2027, Incyte Feb 8, 2027.
How each one makes money: Exelixis revenue · Incyte revenue
Share prices on one chart
Exelixis and Incyte, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Exelixis EXELNASDAQ · Biotechnology | Incyte INCYNASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $15.8B | $23.4B |
| Revenue, last fiscal year | $2.32B | $5.14B |
| Net income, last fiscal year | $783M | $1.29B |
| Net marginNet income as a share of revenue | 33.7% | 25.0% |
| Free cash flow | $876M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Incyte against
Common questions
How is Exelixis different from Incyte?
Exelixis (EXEL) is in Biotechnology on NASDAQ, with $2.32B of revenue in its last fiscal year and a net margin of 33.7%. Incyte (INCY) is in Biotechnology on NASDAQ, with $5.14B of revenue in its last fiscal year and a net margin of 25.0%. The biggest part of Exelixis's revenue is CABOMETYX (91%); at Incyte it is JAKAFI (60%). The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Exelixis and Incyte compare in size?
Incyte has the larger market value: Exelixis $15.8B and Incyte $23.4B, at the last close.
Whose share price rose more over the last 12 months, EXEL or INCY?
Over the last 12 months Exelixis moved +54.7% and Incyte +12.6%. Past price moves say nothing about the future.
Which has had more insider buying, Exelixis or Incyte?
Since 2006, Incyte insiders reported 503 open-market purchases against 114 for Exelixis. These are counts of what was filed, not a view on either stock.
Do members of Congress trade EXEL or INCY?
In the last 12 months, members of Congress disclosed 0 trades in Exelixis (EXEL) and 0 in Incyte (INCY).
When did insiders last buy EXEL and INCY?
Exelixis: Nov 26, 2025. Incyte: Mar 10, 2022.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Exelixis pageIncyte pageRare insider trades this weekAll comparisons
https://oqro.io/compare/exel-vs-incy







